Key result
Modulating cardiac sympathetic drive via the central autonomic network shows promise for diabetic cardiac autonomic neuropathy.
Why the study?
Current treatments for diabetic cardiac autonomic neuropathy are often ineffective because they target peripheral symptoms rather than central sympathoexcitatory origins.
Targeting the central autonomic network to modulate cardiac sympathetic drive presents a promising novel therapeutic avenue for treating diabetic cardiac autonomic neuropathy.
Hypothesis-generating for central autonomic modulation in diabetic cardiac autonomic neuropathy; prospective trials required before clinical consideration.
Diabetic heart disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). A major yet frequently under-recognized component of diabetic heart disease is cardiac autonomic neuropathy (CAN), a condition characterized by dysregulated sympathetic and parasympathetic drive to the heart. Current pharmacological treatments for diabetic CAN are often ineffective, having been extrapolated from other health conditions. These therapies predominantly target the peripheral symptoms of elevated sympathetic activity, whilst largely neglecting its origins in sympathoexcitatory regions of the central autonomic network. Sympathetic control of cardiac function originates from the hypothalamus, medulla oblongata, midbrain, and pons, and is relayed through the intermediolateral cell column of the thoracic spinal cord and the intrinsic cardiac nervous system. Targeting the central autonomic network to modulate cardiac sympathetic drive presents a promising novel therapeutic avenue for the treatment of diabetic CAN. This review briefly summarizes established knowledge regarding the pathophysiology and management of diabetic CAN, and the implications of recent findings of increased neuronal activation in central sympathoregulatory regions early in the development of T2DM. Increased cardiac sympathetic in the intital stages of T2DM might represent a novel therapeutic target to reduce the impact of CAN and thereby improve outcomes in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Sethi et al. (2025) conducted a review in Type 2 diabetes mellitus and cardiac autonomic neuropathy. Targeting the central autonomic network was evaluated. Targeting the central autonomic network to modulate cardiac sympathetic drive presents a promising novel therapeutic avenue for the treatment of diabetic cardiac autonomic neuropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: